Popular Keywords
Vaccine Development & Technologies
mRNA vaccines
DNA vaccines
Recombinant vaccines
Viral vector vaccines
Live attenuated vaccines
Advances in Vaccines, 2025, Volume 1, Issue 1, Pages: 1-4
Covid-19 Vaccine-Induced Chronic False Positive Rapid Plasma Reagin (Rpr) Tests.
Correspondence to Author: Davita Pav.
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33146, USA
Abstract:
People who receive frequent coronavirus disease 2019 (COVID-19) vaccinations may show persistent reactive plasmin reagin (RPR) responses,
as there have been reports of false positive RPR reactivity after a COVID-19 vaccination. Here, we aimed to examine the potential for chronic
false RPR reactivity in a longitudinal cohort caused by repeated mRNA COVID-19 vaccinations. Manual RPR card assays were used to screen
for RPR reactivity in 119 participants in a longitudinal SARS-CoV-2 cohort study that was approved by the IRB (#20201026). Additional testing
was performed on samples that produced reactive results, such as confirmatory fluorescent treponemal antibody (FTA-ABS) testing, anti-nuclear
antibody (ANA) testing, and follow-up RPR screening at additional timepoints. Medical histories were gathered.Following booster vaccination,
we saw (n = 2) screen-positive RPR results (1.7% [2/119]), with two individuals displaying persistent, vaccine-induced RPR reactivity for up
to nine months. Both individuals tested negative for ANA. Clinicians must be aware of the possibility that COVID-19 vaccines may interfere
immunologicly with common infectious disease tests, such as RPR testing. Detailed medical histories and clinical contexts, including recent
vaccination, should be reviewed prior to proceeding with distressing and invasive workups.
Keywords: COVID-19; RPR; ID assay.
Citation:
Dr.Davita Pav, Covid-19 Vaccine-Induced Chronic False Positive Rapid Plasma Reagin (Rpr) Tests. Advances in Vaccines 2025.
Journal Info
- Journal Name: Advances in Vaccines
- DOI: 10.52338/aiv
- Short Name: AIV
- Acceptance rate: 75%
- Volume: 1 (2025)
- Submission to acceptance: 25 days
- Acceptance to publication: 10 days
OUR PUBLICATION BENEFITS
- International Reach
- Peer Review
- Rapid Publication
- Open Access
- High Visibility